Evidence map›Paper›PMID 35008675›Full record

ReviewInternational journal of molecular sciences2021

Modulation of Mesenchymal Stem Cells for Enhanced Therapeutic Utility in Ischemic Vascular Diseases.

Sally L Elshaer, Salma H Bahram, Pranav Rajashekar, Rajashekhar Gangaraju, Azza B El-Remessy

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Sally L ElshaerDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-6462-8169
Salma H BahramDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Misr International University, Cairo 19648, Egypt.
Pranav RajashekarDepartment of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Rajashekhar GangarajuDepartments of Ophthalmology & Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN 38152, USA.ORCID 0000-0002-6664-8286
Azza B El-RemessyDepartment of Pharmacy, Doctors Hospital of Augusta, Augusta, GA 30909, USA.ORCID 0000-0003-4386-1989
University of Tennessee Health Science Center · USDoctors Hospital · USMansoura University · EGMisr International University · EG

Funding

Vascular and Neuronal Repair with Adipose Stromal Cells in RetinopathyR01EY023427 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI GANGARAJU, RAJASHEKHAR · 2013 to 2017
$1.8M
Molecular Mechanisms of diabetic retinopathyR01EY022408 · NEI · UNIVERSITY OF GEORGIA · PI EL-REMESSY, AZZA B · 2012 to 2016
$1.5M
NEI NIH HHS EY022408NEI NIH HHS EY023427
6 · The paper itself

Abstract

Mesenchymal stem cells are multipotent stem cells isolated from various tissue sources, including but not limited to bone marrow, adipose, umbilical cord, and Wharton Jelly. Although cell-mediated mechanisms have been reported, the therapeutic effect of MSCs is now recognized to be primarily mediated via paracrine effects through the secretion of bioactive molecules, known as the "secretome". The regenerative benefit of the secretome has been attributed to trophic factors and cytokines that play neuroprotective, anti-angiogenic/pro-angiogenic, anti-inflammatory, and immune-modulatory roles. The advancement of autologous MSCs therapy can be hindered when introduced back into a hostile/disease environment. Barriers include impaired endogenous MSCs function, limited post-transplantation cell viability, and altered immune-modulatory efficiency. Although secretome-based therapeutics have gained popularity, many translational hurdles, including the heterogeneity of MSCs, limited proliferation potential, and the complex nature of the secretome, have impeded the progress. This review will discuss the experimental and clinical impact of restoring the functional capabilities of MSCs prior to transplantation and the progress in secretome therapies involving extracellular vesicles. Modulation and utilization of MSCs-secretome are most likely to serve as an effective strategy for promoting their ultimate success as therapeutic modulators.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsClinical Trials as TopicHumansIschemiaMesenchymal Stem CellsVascular DiseasesWound Healingangiogenesisimmune modulationinflammationischemic heart diseaseischemic retinamesenchymal stem cells (MSCs)peripheral limb ischemiarepairscarwound healing

Identifiers

PMID35008675
PMCPMC8745455
OpenAlexW4200504139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.